---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000043"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-06-17T20:05:28+00:00"
generated_at: "2026-06-17T20:14:50.486307+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rigel closes VEPPANU license with Arvinas/Pfizer; pays $70M upfront

## Summary
- Rigel gains exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant).
- One-time upfront payment of $70 million made to Arvinas Inc., Arvinas Operations, Arvinas Estrogen Receptor, and Pfizer.
- License agreement previously disclosed on May 12, 2026; HSR waiting period terminated early.
- No additional upfront or milestone payment details provided beyond the $70 million.

## SEC filing metadata
- accession: 0001034842-26-000043
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-06-17T20:05:28+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/0001034842-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/rigl-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000043
- JSON: https://secwatch.observer/filing/0001034842-26-000043.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000043.txt

## Key facts
- M&A Transactions
  RIGEL PHARMACEUTICALS INC completed an acquisition involving Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. for $70.0 million.
  - Action: acquisition
  - Counterparty: Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.
  - Consideration: $70.0 million
  source text: Following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of the other closing conditions under the License Agreement, the License Agreement became effective and the transactions contemplated thereby were completed. In connection therewith, the Company paid the Licensors a one-time upfront payment of $70.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/0001034842-26-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.